Pacira BioSciences (PCRX) Expected to Announce Earnings on Tuesday

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect Pacira BioSciences to post earnings of $0.73 per share and revenue of $183.11 million for the quarter.

Pacira BioSciences Stock Performance

Shares of PCRX stock traded up $0.57 during mid-day trading on Friday, reaching $22.39. 159,444 shares of the company's stock traded hands, compared to its average volume of 796,304. Pacira BioSciences has a 12 month low of $11.16 and a 12 month high of $27.64. The firm has a 50 day moving average price of $24.34 and a two-hundred day moving average price of $24.46. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.99 and a current ratio of 2.41. The firm has a market capitalization of $1.04 billion, a PE ratio of -9.79 and a beta of 0.48.

Insider Buying and Selling

In other Pacira BioSciences news, SVP Lauren Riker sold 5,578 shares of the business's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total value of $146,199.38. Following the sale, the senior vice president owned 59,564 shares in the company, valued at $1,561,172.44. The trade was a 8.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.40% of the stock is currently owned by insiders.

Institutional Trading of Pacira BioSciences

Several hedge funds have recently bought and sold shares of PCRX. Strs Ohio purchased a new stake in shares of Pacira BioSciences during the 1st quarter valued at about $75,000. Goldman Sachs Group Inc. increased its position in shares of Pacira BioSciences by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company's stock worth $27,454,000 after acquiring an additional 367,869 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Pacira BioSciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company's stock worth $677,000 after acquiring an additional 1,165 shares during the period. Hedge funds and other institutional investors own 99.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PCRX. Truist Financial raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price objective for the company in a research report on Friday. Needham & Company LLC dropped their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a report on Friday, May 9th. HC Wainwright increased their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research note on Tuesday, April 8th. Finally, Wall Street Zen upgraded Pacira BioSciences from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.00.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.